argenx to Participate at Upcoming Investor Conferences
argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced its management team's participation in two upcoming investor conferences in November 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced its management team's participation in two upcoming investor conferences in November 2024. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 2:30 p.m. ET in Boston, and attend investor meetings at the Jefferies London Healthcare Conference on November 20-21 in London. A live webcast of the Guggenheim fireside chat will be available on the company's website, with a replay accessible for approximately 90 days.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was +2.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
November 5, 2024
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:
- Guggenheim Inaugural Healthcare Innovation Conference. Fireside chat on Tuesday, November 12, 2024 at 2:30 p.m. ET in Boston, MA.
- Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 20 and Thursday November 21, 2024 in London, UK.
A live webcast of the Guggenheim fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the fireside chat.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.